Medscape: AFIRE encourages less antiplatelet use with novel oral anticoagulant for atrial fibrillation treatment
UC cardiologist weighs in on trial looking at therapies for heart patients
Medscape turned to the expertise of Richard Becker, MD, Director, UC Heart, Lung and Vascular Institute, when reporting the results of a randomized trial comparing an oral anticoagulation with an antiplatelet agent versus an oral anticoagulation alone in patients with both atrial fibrillation and stable coronary artery disease. Becker, also director of the UC Division of Cardiovascular Health and Disease in the College of Medicine and a UC Health cardiologist, authored a New England Journal of Medicine editorial on the results of the AFIRE trial.
Richard Becker, MD
Related Stories
High Court offers protections for therapy speech
April 5, 2026
Jennifer Bard, a professor in the Donald P. Klekamp College of Law and the UC Department of Internal Medicine, spoke with journalists about the US Supreme Court ruling granting first amendment protections for speech offered during therapy sessions.
UC names Suzanne Judd, PhD, as inaugural director of new Center for Public Health
April 2, 2026
Following an extensive national search, the University of Cincinnati College of Medicine has appointed Suzanne E. Judd, PhD, as the inaugural director of its newly established Center for Public Health. Judd, a renowned epidemiologist and interdisciplinary scholar, will lead the center’s mission to transform community health through innovative research, education and strategic advocacy.
Could GLP-1s help curb the opioid crisis?
April 1, 2026
The University of Cincinnati's John Winhusen was featured in a Rolling Stone article discussing the potential for GLP-1s to treat substance abuse disorders.